BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16896265)

  • 1. No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.
    Kumagai A; Namba H; Takakura S; Inamasu E; Saenko VA; Ohtsuru A; Yamashita S
    Endocr J; 2006 Oct; 53(5):615-20. PubMed ID: 16896265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of COT is related to recurrence of papillary thyroid cancer.
    Lee J; Jeong S; Park JH; Lee CR; Ku CR; Kang SW; Jeong JJ; Nam KH; Shin DY; Lee EJ; Chung WY; Jo YS
    Medicine (Baltimore); 2015 Feb; 94(6):e548. PubMed ID: 25674762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
    Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
    Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
    Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
    Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural snapshots of RAF kinase interactions.
    Rezaei Adariani S; Buchholzer M; Akbarzadeh M; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
    Biochem Soc Trans; 2018 Dec; 46(6):1393-1406. PubMed ID: 30381334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
    Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
    Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE
    Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.